Vir Biotechnology/$VIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
408
Website
VIR Metrics
BasicAdvanced
$701M
-
-$4.22
1.23
-
Price and volume
Market cap
$701M
Beta
1.23
52-week high
$14.45
52-week low
$4.32
Average daily volume
1.2M
Financial strength
Current ratio
6.79
Quick ratio
5.839
Long term debt to equity
8.447
Total debt to equity
9.206
Profitability
EBITDA (TTM)
-570.61
Gross margin (TTM)
-2,162.53%
Net profit margin (TTM)
-2,769.04%
Operating margin (TTM)
-2,797.18%
Effective tax rate (TTM)
0.24%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-23.52%
Return on equity (TTM)
-44.59%
Valuation
Price to revenue (TTM)
33.246
Price to book
0.67
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-1.643
Free cash flow yield (TTM)
-60.87%
Free cash flow per share (TTM)
-3.086
Growth
Revenue change (TTM)
-73.79%
Earnings per share change (TTM)
5.22%
3-year revenue growth (CAGR)
-79.22%
3-year earnings per share growth (CAGR)
-22.27%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
Bulls say / Bears say
Vir Biotechnology's strong cash position, with cash and equivalents of $273.6 million and short-term investments of $528.1 million as of Q1 2025, provides financial flexibility for ongoing operations and R&D investments. (marketbeat.com)
The company's exclusive worldwide license agreement with Sanofi, finalized in September 2024, grants access to three clinical-stage masked T-cell engagers, potentially enhancing its oncology pipeline. (finance.yahoo.com)
Positive results from the SOLSTICE Phase 2 clinical trial for chronic hepatitis delta, with 80% virologic response at Week 60, support the initiation of the Phase 3 ECLIPSE registrational program in early 2025. (stocktitan.net)
Vir Biotechnology reported a 94.6% year-over-year decline in total revenue to $3.03 million in Q1 2025, primarily due to the expiration of COVID-related product sales. (marketbeat.com)
The company announced a workforce reduction of approximately 25% in August 2024, indicating a strategic shift away from infectious disease research, which may impact future growth prospects. (medicalupdateonline.com)
Vir Biotechnology's net loss widened to $120.965 million in Q1 2025 from $65.276 million in Q1 2024, reflecting ongoing unprofitability and increased R&D expenses. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
VIR News
AllArticlesVideos
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire·1 day ago
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
Business Wire·1 week ago
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $701M as of August 01, 2025.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of August 01, 2025.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.